替考拉宁治疗革兰阳性菌引起的烧伤患者感染的疗效与安全性评价

Efficacy and safety of teicoplanin in the treatment of Gram-positive bacterial infections in burns patients

目的评价替考拉宁用于治疗烧伤患者由革兰阳性菌引起的感染的疗效、安全性.方法采用多中心、开放、随机研究单组评估设计,按照每次400mg,首日2次,此后每日1次的方法给药,疗程5～7d.结果替考拉宁治疗50例革兰阳性菌感染烧伤患者总细菌清除率为84.0%,创面感染的临床征象及全身反应明显缓解,未发生不良反应.结论替考拉宁对临床治疗革兰阳性菌,特别是耐甲氧西林金黄色葡萄球菌(MRSA)引起的烧伤感染有良好的疗效,不良反应少.

To evaluate the efficacy and safety of teicoplanin in the treatment of Gram-positive bacterial infection in burns patients. A multi-central open randomized trial was performed to access the cure rates of burn patients with Gram-positive bacterial infection. A total of 50 burn patients infected with Gram-positive bacteria were enrolled in this study. Each patient was administered teicoplanin （dosage： 400mg once）, twice in the first day, then once a day in the following 5～7 days. Bacterial clearance rate was about 84% and all patients experienced relief from clinical infectious symptoms, signs and systemical reactions. No adverse drug reaction occurred during this study. Result showed that teicoplanin was an effective and safe antibiotic in the treatment of Gram-positive bacterial burn infections, especially for MRSA infection in burn centers.